Thu. 25 Apr 2024, 7:36am ET
Benzinga
Biotech, News, Health Care, General
- Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye)
- Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet.